Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention

Figures & data

Figure 1. Decision-Analytic Model Schematic.

Table 1. Input parameters.

	Endovascular Intervention
	Eluvia		Zilver PTX
Clinical Input Parameter	Mean	SD	Mean	SD	Source
Loss of Primary Patency	17.0%	2.1%	22.9%	3.4%	14,15
Target Lesion Revascularization	12.7%	2.0%	20.1%	3.5%	14,15
Major Amputation Target Limb	1.5%	0.7%	0.7%	0.7%	14,15
Death	7.1%	1.5%	8.3%	2.3%	14,15
Cost Input Parameter
Initial Endovascular Intervention	$16,848	$16,848	$16,848	$16,848	Analysis of Medicare Claims and Administrative Data*
Target Lesion Revascularization	$23,094	$23,094	$23,094	$23,094
Major Amputation Target Limb	$43,629	$43,629	$43,629	$43,629	22

*See Methods section for complete explanation of approach used.

Table 2. Base Case Microsimulation.

	Endovascular Intervention
	Eluvia	Zilver PTX	(Eluvia - Zilver PTX)
Cost Per Patient
Mean	$20,010	$21,356	Δ −$1,346
95% CI	$19,840–$20,180	$21,172–$21,540	–
Expected TLR-Free
Mean	88.4%	81.0%	Δ + 7.4%
95% CI	87.8%–89.1%	80.3%–81.8%	–

CI: confidence interval.

Figure 2. Each dot represents one simulation of the 1,000 performed in the probabilistic sensitivity analysis in which cohorts of 10,000 patients entered each treatment arm of the model one at a time and were exposed to the risks of clinical events and costs for up to two years after the initial procedure. The coordinates of each dot are the difference in cost (Eluvia-Zilver PTX: y-axis) divided by the difference in TLR (Zilver PTX-Eluvia: x-axis).

Figure 3. One-Way Sensitivity Analysis. Vertical line indicates no difference in cost between the two interventions.

Data availability statement

The data that support the findings of this study are available upon reasonable request.